Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The BCMA bonanza

A long and growing list of anti-BCMA candidates — including chimeric antigen receptor-T cell therapies, antibody–drug conjugates and bispecific antibodies — are contending to transform multiple myeloma treatment.
  1. Asher Mullard
    View author publications

    You can also search for this author in PubMed  Google Scholar

Great targets are scarce, and so researchers across the biopharmaceutical industry tend to pile in when they come along. And when the biology is just right, such targets promise not just new therapeutic options and commercial opportunities, but also rare chances to explore emerging drug modalities. BCMA, for the treatment of multiple myeloma, is the latest case in point.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 18, 481-484 (2019)

doi: https://doi.org/10.1038/d41573-019-00105-9

Updates & Corrections

  • Correction 17 June 2019: The development status of LCAR-B38M in Table 1 has been modified to phase II alone globally and the alternative code name JNJ-4528 has been added.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links